2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.58 (Poster) Real-World Outcomes in Patients INTRODUCTION METHODS With EGFR Wildtype Nonsquamous Locally Advanced/ Metastatic NSCLC Receiving Second- or Third-Line Docetaxel: Pooled Analysis From LUMINATE-101

PP01.58 (Poster) Real-World Outcomes in Patients INTRODUCTION METHODS With EGFR Wildtype Nonsquamous Locally Advanced/ Metastatic NSCLC Receiving Second- or Third-Line Docetaxel: Pooled Analysis From LUMINATE-101

Back to course

Pdf Summary

The study aimed to evaluate the treatment landscape and real-world outcomes for patients with EGFR wildtype non-squamous advanced/metastatic NSCLC who have experienced progression during or following first-line therapies. The most common treatment regimens were first-line platinum-based chemotherapy with or without immunotherapy, and second-line docetaxel chemotherapy with or without ramucirumab or bevacizumab. Real-world outcomes for these treatments were poor, with an overall survival of 7 months. This highlights the need for more effective therapies in treating patients with EGFR wildtype non-squamous advanced/metastatic NSCLC.<br /><br />The study included patients with confirmed non-squamous advanced or metastatic NSCLC who had received at least one line of platinum-based chemotherapy with or without immunotherapy and docetaxel in the second or third line. Patients who had tested negative for EGFR mutation and had not received any EGFR tyrosine kinase inhibitors were included. The study found that the median time to next treatment or death was 4.99 months, the median progression-free survival was 3.48 months, and the median overall survival was 6.44 months.<br /><br />These results indicate that current standard-of-care treatments for EGFR wildtype non-squamous advanced/metastatic NSCLC have limited efficacy and there is a need for more effective therapies. The study also highlights the importance of identifying suitable patient populations for newly developed therapeutics. Further research is needed to develop therapies that target novel biomarkers, such as c-Met overexpression, which has shown promising results in previously treated patients. Overall, this study provides insights into the real-world outcomes of different treatment regimens for EGFR wildtype non-squamous advanced/metastatic NSCLC and emphasizes the need for improved therapeutic options.

Asset Subtitle

Qingqing Xu

Keywords

treatment landscape

real-world outcomes

EGFR wildtype

advanced NSCLC

metastatic NSCLC

progression

platinum-based chemotherapy

immunotherapy

docetaxel chemotherapy

overall survival